Key result
Fourth-generation cryoballoon achieves similar real-time recording rates as earlier devices but speeds pulmonary vein isolation.
Why the study?
The novel fourth-generation cryoballoon (CB-Advance PRO) with a shortened catheter tip was recently introduced, but its feasibility and acute efficacy for PVI required evaluation.
Does the fourth-generation cryoballoon (CB-Advance PRO) improve procedural efficacy compared to the second-generation cryoballoon in patients with symptomatic, drug-refractory atrial fibrillation?
Cohort (n=200)
Yes
Does the fourth-generation cryoballoon (CB-Advance PRO) improve procedural efficacy compared to the second-generation cryoballoon in patients with symptomatic, drug-refractory atrial fibrillation?
The fourth-generation cryoballoon is feasible and significantly reduces time to pulmonary vein isolation and total freezing time compared to the second-generation device, without a significant increase in acute complications.
Answers are grounded in this paper and cite their sources.
Shorter isolation times may enhance procedural efficiency; leaves open long-term outcome benefits versus second-generation devices.
BACKGROUND: The second-generation cryoballoon (CB2) is widely used for pulmonary vein (PV) isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). Recently, the novel fourth-generation CB (CB-Advance PRO) was introduced, incorporating a shortened catheter tip. HYPOTHESIS: The aim of this study was to evaluate the feasibility and acute efficacy of PVI using the CB-Advance PRO. METHODS: A total of 200 consecutive patients were analyzed. Hundred patients who underwent PVI due to symptomatic, drug-refractory AF were treated with the CB-Advance PRO (group I) and were included into this multicenter analysis. A group of 100 patients were treated with the CB2 and acted as controls (group II). RESULTS: In total, 739 of 739 PVs (100%) were successfully isolated. There was a nonsignificant trend in the incidence of online registration of PV signals between both groups (group I: 77.9% vs group II: 71.4%, P = .09). Median time to PVI (time to isolation [TTI]) and mean total freezing time were significantly shorter when using the CB-Advance PRO (group I: 33 [23, 50] vs group II: 40 [26, 60] seconds and group I: 166 ± 29 vs group II: 183 ± 38 seconds, P < .01). In three of 100 (3%) patients of group I and one of 100 (1%) patients of group II, a transient phrenic nerve palsy occurred (P = .62). CONCLUSION: The use of the novel CB-Advance PRO is feasible and associated with a significant reduction in mean TTI and mean total freezing time as compared to the CB2.
No takes yet. Share an insight, caveat, or question.
Rottner et al. (2020) conducted a cohort in Paroxysmal or persistent symptomatic, drug-refractory atrial fibrillation (n=200). Fourth-generation cryoballoon (CB-Advance PRO) vs. Second-generation cryoballoon (CB2) was evaluated on Incidence of real-time recordings (online registration of PV signals) (p=0.09). The fourth-generation cryoballoon achieved 100% acute pulmonary vein isolation and a nonsignificant trend toward higher real-time recording of pulmonary vein signals while reducing median time to isolation compared to the second-generation device.
Synapse has enriched 10 related papers. Consider them for comparative context: